Simulations Plus, Inc. Reports Earnings Results for the Second Quarter Ended February 28, 2021
April 12, 2021 at 04:05 pm EDT
Share
Simulations Plus, Inc. announced earnings results for the second quarter ended February 28, 2021. For the second quarter, the company announced sales was USD 13.147 million compared to USD 10.350 million a year ago. Operating income was USD 3.486 million compared to USD 2.826 million a year ago. Net income was USD 3.211 million compared to USD 2.150 million a year ago. Basic earnings per share from continuing operations was USD 0.16 compared to USD 0.12 a year ago. Diluted earnings per share from continuing operations was USD 0.15 compared to USD 0.12 a year ago. For the half year, sales was USD 23.848 million compared to USD 19.751 million a year ago. Operating income was USD 6.537 million compared to USD 5.545 million a year ago. Net income was USD 5.690 million compared to USD 4.208 million a year ago. Basic earnings per share from continuing operations was USD 0.28 compared to USD 0.24 a year ago. Diluted earnings per share from continuing operations was USD 0.27 compared to USD 0.23 a year ago.
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
SIMULATIONS PLUS, INC. 
